Brodalumab - Psoriasis

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed to adopt the SERMOG high-cost drugs pathway.for adiults with psoriasis

The Prescribing Clinical Network recommends Brodalumab as a treatment option for moderate to severe plaque psoriasis in line with NICE TA511 (March 2018).

Brodalumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians)

Brodalumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.